Drug Trial Radar · NCT05100862
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
799
Actual
Start
Mar 10, 2022
Primary completion
Jul 2028
Study completion Jun 2030
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Oct 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Conditions
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma
Interventions
ZanubrutinibDrug
Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
RituximabDrug
Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
LenalidomideDrug
Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
ObinutuzumabDrug
Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)Time frame: Approximately 78 months
Locations
264 sites in 28 countries. Site status is shown where the registry gives one.
Ucsf Fresno University of California San Francisco Fresno
Fresno, California
Kaiser Permanente Southern California
Irvine, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
Los Angeles Cancer Network
Los Angeles, California
Valkyrie Clinical Trials
Los Angeles, California
UCLA Hematologyoncology
Los Angeles, California
Scripps Health
San Diego, California
Sharp Healthcare Sharp Memorial Hospital
San Diego, California
Baptist Md Anderson Cancer Center
Jacksonville, Florida
Ascension Sacred Heart
Pensacola, Florida
Northwest Georgia Oncology Centers Marietta
Marietta, Georgia
Cancer Care Specialists of Illinois
OFallon, Illinois
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
Mission Cancer and Blood
Waukee, Iowa
Cotton Oneil Cancer Center
Topeka, Kansas
Cancer Center of Kansas
Wichita, Kansas
Baptist Health Lexington
Lexington, Kentucky
Christus Highland Cancer Treatment Center
Shreveport, Louisiana
Luminis Health Anne Arundel Medical Center
Annapolis, Maryland
The University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Ascension St Agnes Hospital
Baltimore, Maryland
American Oncology Partners of Maryland Pa
Bethesda, Maryland
Henry Ford Hospital
Detroit, Michigan
Corewell Health the Michigan Cancer Consortium
Grand Rapids, Michigan
Hattiesburg Hematology and Oncology Clinic
Hattiesburg, Mississippi
University of Missouri Hospital Ellis Fischel Cancer Center
Columbia, Missouri
Oncology Hematology Associates
Springfield, Missouri
St Vincent Frontier Cancer Center
Billings, Montana
Nebraska Cancer Specialists
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Iyengar Hematology Oncology Medical Center Pa
Bayonne, New Jersey
Summit Medical Group
Florham Park, New Jersey
New York Cancer and Blood Specialists
Shirley, New York
Suny Upstate Medical University
Syracuse, New York
North Shore Hematology Oncology Associates Eccc Bronx
The Bronx, New York
Optum Medical Care, Pc
Westbury, New York
Levine Cancer Institute Wake Forest
Charlotte, North Carolina
Oncology Hematology Care Clinical Trials, Llc
Cincinnati, Ohio
Va Northeast Ohio Healthcare System
Cleveland, Ohio
Toledo Clinic Cancer Center
Toledo, Ohio
Showing 40 of 264 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.